Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reproductive Biology and Endocrinology
Published in: Reproductive Biology and Endocrinology 1/2003

Open Access 01-12-2003 | Review

Thrombophilia and pregnancy

Author: Michael J Kupferminc

Published in: Reproductive Biology and Endocrinology | Issue 1/2003

Login to get access

Abstract

Pregnancy is hypercoagulable state. The field of thrombophilia; the tendency to thrombosis, has been developed rapidly and has been linked to many aspects of pregnancy. It is recently that severe pregnancy complications such as severe preeclampsia intrauterine growth retardation abruptio placentae and stillbirth has been shown to be associated with thrombophilia. Recurrent miscarriage and has also been associated with thrombophilia. Finally, thromboembolism in pregnancy as in the non-pregnant state is linked to thrombophilia. In this review all aspects of thrombophilia in pregnancy are discussed, and also all prophylactic and therapeutic implications.
Literature
1.
Dahlback B: Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis. 1994, 24: 139-151.PubMed
2.
Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994, 369: 64-67. 10.1038/369064a0.PubMedCrossRef
3.
Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994, 330: 517-552. 10.1056/NEJM199402243300801.PubMedCrossRef
4.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996, 88: 3698-3703.PubMed
5.
Maertinelli I, Sagghi E, Landi G, Taioli E, Duca F, Mannucci PM: High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in the user of oral contraceptives. N Engl J Med. 1988, 338: 1793-1797. 10.1056/NEJM199806183382502.CrossRef
6.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995, 10: 111-113.PubMedCrossRef
7.
Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van OostBA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ: Molecular genetic analysis in mild hyperhomocystinemia: a common mutation in the methylene-tetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996, 58: 35-41.PubMedCentralPubMed
8.
9.
Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996, 27: 517-527. 10.1016/0735-1097(95)00508-0.PubMedCrossRef
10.
Sebastio G, Sperandeo MP, Panico M, de Franchis R, Kraus JP, Andria G: The molecular basis of homocysteinuria due to cystathionie beta-synthase deficiency in Italian families, and report for four novel mutations. Am J Hum Genet. 1995, 56: 1324-1333.PubMedCentralPubMed
11.
Roberts JM, Taylor RN, Musici TJ, Rodgers GM, Hubel CA, McLaughlin MK: Preeclampsia an endothelial cell disorder. Am J Obstet Gynecol. 1989, 161: 1200-1204.PubMedCrossRef
12.
Salafia CM, Pezzulo JC, Lopez-Zeno JA, Minior VK, Vintzileos AM: Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol. 1995, 173: 1079-1105.CrossRef
13.
Shanklin DR, Sibai BM: Ultrastructural aspects of preeclampsia. Am J Obstet Gynecol. 1989, 161: 735-741.PubMedCrossRef
14.
Khong TY, Pearce JM, Robertson WB: Acute atherosis in preeclampsia: maternal determination and fetal outcome in the presence of the lesion. Am J Obstet Gynecol. 1987, 157: 360-363.PubMedCrossRef
15.
Salafia CM, Minior VK, Pezzulo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM: Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am J Obstet Gynecol. 1995, 173: 1049-1057.PubMedCrossRef
16.
Greer IA: Thrombosis in Pregnancy: Maternal and Fetal Issues. Lancet. 1999, 353: 1258-1265. 10.1016/S0140-6736(98)10265-9.PubMedCrossRef
17.
Seligsohn U, Zivelin A: Thrombophilia As a Multigenic Disorder. Thromb Haemost. 1997, 78: 297-301.PubMed
18.
Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB: Prothrombin and Factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000, 342: 374-380. 10.1056/NEJM200002103420602.PubMedCrossRef
19.
Greer IA: The Challenge of Thrombophilia in Maternal-Fetal Medicine. N Engl J Med. 2000, 342: 424-425. 10.1056/NEJM200002103420610.PubMedCrossRef
20.
Green JR: Placenta previa and abruptio placentae. In: Maternal Fetal Medicine: Principles and Practice. Edited by: Creasy RK, Resnik R. 1994, Philadelphia: W.B. Saunders, 609-610.
21.
Infante-Rievard C, David M, Gauthier R, Ribard GE: Lupus anticoagulants, anticardiolipin antibodies and fetal loss. N Engl J Med. 1991, 325: 1063-1066.CrossRef
22.
Dekker GA, Sibai BM: Etiology and pathophysiology of preeclampsia Current concepts. AJOG Review. Am J Obstet Gynecol. 1998, 179: 1359-1375.PubMedCrossRef
23.
Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ: Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol. 2001, 98: 1041-1044. 10.1016/S0029-7844(01)01621-0.PubMedCrossRef
24.
Mousa HA, Alfirevic Z: Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?. Hum Reprod. 2000, 15: 1830-1833. 10.1093/humrep/15.8.1830.PubMedCrossRef
25.
Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG: Placental pathology in early onset pre-eclampsia and intra-uterinegrowth restriction in women with and without thrombophilia. Placenta. 2002, 23: 337-342. 10.1053/plac.2001.0785.PubMedCrossRef
26.
Arias F, Romero R, Joist H, Kraus FT: Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med. 1998, 7: 277-286.PubMedCrossRef
27.
Alarcon-Segovia D, Delete M, Oria CV, Sanchez-Guerrero J, Gomet-Pacheco L, Cabiedes I, Fernandez L, Ponce de Leon S: Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine. 1989, 68: 353-365.PubMed
28.
Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR: The "primary" anti-phospholipid syndrome: major clinical and serological features. Medicine. 1989, 68: 366-374.PubMedCrossRef
29.
30.
Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, Harpel PC: Pregnancy loss in the antiphospholid-antibody syndrome – a possible thrombogenic mechanism. N Engl J Med. 1997, 337: 154-160. 10.1056/NEJM199707173370303.PubMedCrossRef
31.
Branch DW, Silver RM, Pierangeli S, van Leeuwen I, Harris EN: Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and anliphospholipid syndrome. Obstet Gynecol. 1997, 89: 549-555. 10.1016/S0029-7844(97)00065-3.PubMedCrossRef
32.
MacLean MA, Cumming GP, McCall F, Walker ID, Wallter JJ: The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. BJOG. 1994, 101: 103-110.CrossRef
33.
Out HJ, Bruinse HW, Christiaens GCML, van Vliet M, Meilof IF, de Groot PG, Smeenk RJ, Derksen RH: Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis. 1991, 50: 553-557.PubMedCentralPubMedCrossRef
34.
Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S: Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol. 1991, 77: 854-858.PubMed
35.
Petri M, Golbus M, Anderson R, Whiting-O'Keefe Q, Corash L, Hellmann D: Antinuclear antibody, lupus antiroagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled prospective study of forty-four women. Arthritis Rheum. 1987, 30: 601-606.PubMedCrossRef
36.
Yetman DL, Kutteh WH: Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril. 1996, 66: 540-546.PubMed
37.
Rai RS, Clifford K, Cohen H, Regan L: High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995, 10: 3301-3304.PubMed
38.
Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW: Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996, 87: 489-493. 10.1016/0029-7844(95)00498-X.PubMedCrossRef
39.
Bocciolone L, Meroni P, Parazrini F, Tincani A, Radici E, Tarantini M, Rossi E, Bianchi C, Mezzanotte C, D'Angelo A: Antiphospholipid antibodies and risk of intrauterine late fetal death. Acta Obstet Gynecol Scand. 1994, 73: 389-392.PubMedCrossRef
40.
Branch DW, Silver RM, Blackwell L, Reading JC, Scott JR: Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992, 80: 614-620.PubMed
41.
Scott RAH: Anti-cardiolipin antibodies and pre-eclampsia. BJOG. 1987, 94: 604-605.CrossRef
42.
Branch DW, Andres R, Digre KB, Rote NS, Scott JR: The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol. 1989, 73: 541-545.PubMed
43.
Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, Blomberg von BME, Jakobs C, Geijn van HP: Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol. 1995, 173: 1042-1048.PubMedCrossRef
44.
Pampus van MG, van MP, Dekker GA, Wolf HW, Huijgens PC, Koopman MMW, Blomberg BME, von Büller HR: High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol. 1999, 180: 1146-1150.CrossRef
45.
Pattison NS, Chamley LW, McKay W, Liggins GC, Butler WS: Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. BJOG. 1993, 100: 909-913.CrossRef
46.
Yasuda M, Takakuwa K, Tokunaga A, Tanaka K: Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995, 86: 555-559. 10.1016/0029-7844(95)00247-O.PubMedCrossRef
47.
Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB: Increased frequency of the genetic thrombophilia in women with complications of pregnancy. N Eng J Med. 1999, 340: 9-13. 10.1056/NEJM199901073400102.CrossRef
48.
Rajah SB, Moodley J, Pudifin D, Duursma J: Anticardiolipin antibodies in hypertensive emergencies. Clin Exp Hypertens B. Hypertension in Pregnancy. 1990, B9: 267-271.CrossRef
49.
Out HJ, Bruinse HW, Christiaens GCML, Van Vliet M, De Groot PG, Nieuwenhuis HK, Derksen RHWM: A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992, 167: 20-26.CrossRef
50.
Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, Emlen Wl: Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med. 1994, 120: 470-475.PubMedCrossRef
51.
Branch DW, Scott JR, Kochenour NK, Hershgold E: Obstetric complications associated with lupus anticoagulant. N Engl J Med. 1985, 313: 1322-1326.PubMedCrossRef
52.
Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Manusco S: Pregnancy outcome in relation to uterine artery now velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet Gynecol. 1993, 82: 970-976.PubMed
53.
Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BI, Hughes GRV: A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996, 14: 131-136.PubMed
54.
Polzin WJ, Kopelman JN, Robinson RD, Read JA, Brady K: The association of antiphospholipid antibodies with pregnancy complicated by fetal growth restriction. Obstet Gynecol. 1991, 78: 1108-1111.PubMed
55.
Dizon-Townson DS, Nelson LM, Easton K, Ward K: The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 1996, 175: 902-5.PubMedCrossRef
56.
Nagy B, Tóth T, Rigó JJR, Karádi I, Romics L, Papp Z: Detection of factor v Leiden in severe pre-eclamptic Hungarian women. Clin genet. 1998, 53: 478-481.PubMedCrossRef
57.
Rigo J, Nagy B, Fintor L, Tanyi J, Beke A, Karadi I, Papp Z: Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy. 2000, 19: 163-172. 10.1081/PRG-100100132.PubMedCrossRef
58.
Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB: Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol. 2000, 96: 45-49. 10.1016/S0029-7844(00)00861-9.PubMedCrossRef
59.
von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G: Incidence of the factor V Leiden mutation, coagulation inhibitor deficiency, and elevated antiphospholipid antibodies in patients with pre-eclampsia or HELLP-syndrome. Thromb Res. 2000, 100: 363-365. 10.1016/S0049-3848(00)00312-1.PubMedCrossRef
60.
Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM: Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol. 2001, 185: 153-157. 10.1067/mob.2001.114691.PubMedCrossRef
61.
Laivuori H, Kaaja R, Ylikorkala O, Hiltunen T, Kontula K: 677 T polymorphism of the MTHFR gene and pre-eclampsia. Obstet Gynecol. 2000, 96: 277-280. 10.1016/S0029-7844(00)00896-6.PubMedCrossRef
62.
Higgins JR, Kaiser T, Moses EK, North R, Brennecke SP: Prothrombin G20210A mutation: is it associated with pre-eclampsia?. Gynecol Obstet Invest. 2000, 50: 254-256. 10.1159/000010326.PubMedCrossRef
63.
Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A: High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and 2nd trimester loss. Acta Obstet Gynecol Scand. 2000, 79: 963-967. 10.1034/j.1600-0412.2000.079011963.x.PubMed
64.
Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W: Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol. 1998, 92: 457-460. 10.1016/S0029-7844(98)00208-7.PubMedCrossRef
65.
Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, Montanaro S, Pavone G, Di Minno G: Factor V Leiden, C >T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 1997, 77: 1052-1054.PubMed
66.
Grandone E, Margaglione M, Colaizzo D, Cappucci G, Scianname N, Montanaro S, Paladini D, Martinelli P, Di Minno G: Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost. 1999, 81: 349-352.PubMed
67.
Shaughnessy KM, Fu B, Ferraro F, Lewis I, Downing S, Morris NH: Factor V Leiden and thermolable methylenetetrahydrofolate reductase gene variants in an east Anglian preeclampsia cohort. Hypertension. 1999, 33: 1338-1341.CrossRef
68.
Sohda S, Arinami T, Hamada HM, Yamada N, Hamaguchi H, Kubo T: Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet. 1997, 34: 525-526.PubMedCentralPubMedCrossRef
69.
Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B: Preeclampsia is associated with reduced response to activated protein C. Am J Obstet Gynecol. 1997, 176: 457-460.PubMedCrossRef
70.
Mello G, Parretti E, Martini E, Mecacci F, La Torre P, Cioni R, Lucchetti R, Fedi S, Gori AM, Pepe G, Prisco D, Abbate R: Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis. 1999, 29: 197-203. 10.1159/000022502.PubMed
71.
Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B: Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost. 1999, 81: 532-537.PubMed
72.
De Groot CJM, Bloemenkamp KWM, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, De Ronde H, Oei SG, Kanhai HHH, Rosendaal FR: Preeclampsia and genetic risk factors for thrombosis: a case control study. Am J Obstet Gynecol. 1999, 181: 975-980.PubMedCrossRef
73.
Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, Greaves M, Vickers MA: Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost. 2002, 87: 779-785. ReviewPubMed
74.
Murphy RP, Donoghue C, Nallen RJ, D'Mello M, Regan C, Whitehead AS, Fitzgerald DJ: Prospective evaluation of the risk conferred by factor V Leiden and the thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol. 2000, 20: 266-270.PubMedCrossRef
75.
Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ, Peraud PJ, Merrill DC: Genetic susceptibility to pre-eclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-basepair insertion at nucleotide 844 of the gene for cystathione-synthase, and factor V Leiden mutation. Am J Obstet Gynecol. 2001, 184: 1211-1217. 10.1067/mob.2001.110411.PubMedCrossRef
76.
Powers RW, Minich LA, Lykins DL, Ness RB, Crombleholme WR, Roberts JM: Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Invest. 1999, 6: 74-79. 10.1016/S1071-5576(98)00052-5.CrossRef
77.
Lachmeijer AMA, Arngrimsson R, Bastiaans EJ, Pals G, ten Kate LP, de Vries JIP, Kostense PJ, Aarnoudse JG, Dekker GA: Mutations in the gene for MTHFR, homocysteine levels, and vitamin status in women with a history of PE. Am J Obstet Gynecol. 2001, 184: 394-402. 10.1067/mob.2001.109393.PubMedCrossRef
78.
Zusterzeel PLM, Visser W, Blom HJ, Peters WHM, Heil SG, Steegers EAP: Methylenetetrahydrofolate reductase polymorphisms in pre-eclampsia and the HELLP syndrome. Hypertens Preg. 2000, 19: 299-307. 10.1081/PRG-100101991.CrossRef
79.
Kaiser T, Brennecke SP, Moses EK: Methylenetetrahydrofolate reductase polymorphisms are not a risk factor for pre-eclampsia/eclampsia in Australian women. Gynecol Obstet Invest. 2000, 50: 100-102. 10.1159/000010291.PubMedCrossRef
80.
Hauge B, Wiltshire E, Nelson P, Dekker G, Robinson J, Thomas D: Polymorphisms of Methylenetetrahydrofolate reductase in women with pre-eclampsia 12th International society for the study of hypertension in pregnancy. Hypertens Pregnancy. 2000, 19: 23-abstract # O46
81.
Rajkovic A, Catlano PM, Malinow MR: Elevated homocysteine levels with preeclampsia. Obstet Gynecol. 1997, 90: 168-171. 10.1016/S0029-7844(97)00223-8.PubMedCrossRef
82.
Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen AL, Ueland PM: Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000, 71: 962-968.PubMed
83.
Cotter AM, Molloy AM, Scott JM, Daly SF: Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Am J Obstet Gynecol. 2001, 185: 781-785. 10.1067/mob.2001.117304.PubMedCrossRef
84.
Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, Sieve-Smith L, Tracy T: The 4G/4G polymorphism of the hypofibrinolytic PAI-1 gene: an independent risk factor for serious pregnancy complications. Metabolism. 2000, 49: 845-852. 10.1053/meta.2000.6749.PubMedCrossRef
85.
Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Eldor A: Increased Frequency of the Hypofibrinolytic 4G/4G Polymorphism of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene in Women with Obstetric Complications. Obstet Gynecol. 2001, 97: 44-48. 10.1016/S0029-7844(00)01094-2.PubMedCrossRef
86.
Sibai BM, Ramadan MK, Chari RS, Friedman SA: Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol. 1995, 172 (1 Pt 1): 125-129.PubMedCrossRef
87.
Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M: Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol. 2002, 186: 422-426. 10.1067/mob.2002.120280.PubMedCrossRef
88.
Sibai BM, Mercer B, Sarinoglu C: Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol. 1991, 165: 1408-1412.PubMedCrossRef
89.
de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP: Hyperhomocystinemia and protein S deficiency in complicated pregnancies. BJOG. 1997, 104: 1248-1254.CrossRef
90.
Martinelli P, Grandone E, Colaizzo D, Paladini D, Scianname N, Margaglione M, Di Minno G: Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica. 2001, 86: 428-431.PubMed
91.
Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinelli P, Di Minni G: low birth-weight in neonates of mothers carrying factor V G1691A and factor A 20210 mutations. Haematologica. 2002, 87: 177-181.PubMed
92.
Infante-Rivard C, Rivard GE, Yotov WV, Génin E, Guiguet M, Weinberg C, Gauthier R, Feoli-Fonseca JC: Absence of Association of Thrombophilia Polymorphisms with Intrauterine Growth Restriction. N Engl J Med. 2002, 347: 19-25. 10.1056/NEJM200207043470105.PubMedCrossRef
93.
Reznik R: Intrauterine growth restriction. Obstet Gynecol. 2002, 99: 490-496. 10.1016/S0029-7844(01)01780-X.CrossRef
94.
Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Landsberg JA: Mid-Trimester Severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG. 2002, 109: 1373-1376.PubMedCrossRef
95.
van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ: Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG. 2000, 107: 785-791.PubMedCrossRef
96.
Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E: Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol. 1998, 179: 1565-1567.PubMedCrossRef
97.
Goddijn-Wessel TA, Wouters MG, van de Molen EF, Spuijbroek MD, Steegers-Theunissen RP, Blom HJ, Boers GH, Eskes TK: Hyperhomocystinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol. 1996, 66: 23-29. 10.1016/0301-2115(96)02383-4.PubMedCrossRef
98.
Regan L, Rai R: Thrombophilia and pregnancy loss. J Reprod Immunol. 2002, 55: 163-180. 10.1016/S0165-0378(01)00144-9. ReviewPubMedCrossRef
99.
Tulppala M, Viinikka L, Ylikorkala O: Thromboxane dominance and prostacyclin deficiency in habitual abortion. Lancet. 1991, 337: 879-881. 10.1016/0140-6736(91)90205-4.PubMedCrossRef
100.
Vincent T, Rai R, Regan L, Cohen H: Increased thrombin generation in women with recurrent miscarriage. Lancet. 1998, 352: 116-10.1016/S0140-6736(98)85022-8.PubMedCrossRef
101.
Woodhams J, Candotti G, Shaw R, Kernoff PBA: Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res. 1989, 55: 99-107.PubMedCrossRef
102.
Rai R, Tuddenham E, Backos M, Regan L: Pre-pregnancy thrombophilic abnormalities are associated with subsequent spontaneous abortion. Hum Reprod. 2000, 15: 168-
103.
Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996, 174: 1584-1589.PubMedCrossRef
104.
Rai R, Cohen H, Dave M, Regan L: Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997, 314: 253-257.PubMedCentralPubMedCrossRef
105.
Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N: Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost. 1999, 82: 6-9.PubMed
106.
Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z: Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 1997, 97: 551-554. 10.1046/j.1365-2141.1997.882901.x.PubMedCrossRef
107.
Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA: Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 1998, 128: 1000-1003.PubMedCrossRef
108.
Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M: Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol. 2000, 43: 31-35. 10.1111/j.8755-8920.2000.430106.x.PubMedCrossRef
109.
Sarig G, Younis JS, Hoffman R, Lanir N, Blumenfeld Z, Brenner B: Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril. 2002, 77: 342-347. 10.1016/S0015-0282(01)02971-5.PubMedCrossRef
110.
Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D: A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod. 1999, 14: 1624-1627. 10.1093/humrep/14.6.1624.PubMedCrossRef
111.
Finan RR, Tamim H, Ameen G, Sharida HE, Rashid M, Almawi WY: Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol. 2002, 71: 300-305. 10.1002/ajh.10223.PubMedCrossRef
112.
Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A, Agorastos T, Zournatzi V, Makris PE, Bontis J, Kotsis A: Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod. 2000, 15: 458-462. 10.1093/humrep/15.2.458.PubMedCrossRef
113.
Reznikoff-Etievan MF, Cayol V, Carbonne B, Robert A, Coulet F, Milliez J: Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG. 2001, 108: 1251-1254. 10.1016/S0306-5456(01)00298-4.PubMed
114.
Alonso A, Soto I, Urgelles MF, Corte JR, Rodriguez MJ, Pinto CR: Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol. 2002, 187: 1337-1342. 10.1067/mob.2002.126849.PubMedCrossRef
115.
Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, Regan L: Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod. 2001, 16: 961-965. 10.1093/humrep/16.5.961.PubMedCrossRef
116.
Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, Scianname N, Pavone G, Di Minno G: Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997, 77: 822-824.PubMed
117.
Kutteh WH, Park VM, Deitcher SR: Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril. 1999, 71: 1048-1053. 10.1016/S0015-0282(99)00133-8.PubMedCrossRef
118.
Dizon-Townson DS, Kinney S, Branch DW, Ward K: The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 1997, 34: 217-223. 10.1016/S0165-0378(97)00039-9.PubMedCrossRef
119.
Deitcher SR, Park VM, Kutteh WH: Methylene tetrahydrofolate reductase 677 T mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood. 1998, 92 (Suppl 1): 117b-
120.
Kornberg A, Raziel A, Rahimini-Levene N, Yona R, Sela BA, Ron-El R: Hypercoagulability and recurrent abortions. Blood. 1998, 92 (Suppl 1): 121b-
121.
Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers CH, Eskes TK: Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr. 1998, 128: 1336-1341.PubMed
122.
Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK: Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril. 2000, 74: 1196-1199. 10.1016/S0015-0282(00)01595-8.PubMedCrossRef
123.
Souza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF: Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod. 1999, 14: 2448-2450. 10.1093/humrep/14.10.2448.PubMedCrossRef
124.
Pickering W, Marriott K, Regan L: G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population. Clin Appl Thromb Hemost. 2001, 7: 25-28.PubMedCrossRef
125.
Deitcher SR, Park VM, Kutteh WH: Prothrombin 20210 G A mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood. 1998, 92 (Suppl 1): 118b-
126.
Pihusch R, Buchholz T, Lohse P, Rubsamen H, Rogenhofer N, Hasbargen U, Hiller E, Thaler CJ: Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol. 2001, 46: 124-131. 10.1111/j.8755-8920.2001.460202.x.PubMedCrossRef
127.
Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH: The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996, 75: 387-388.PubMed
128.
Brenner B: Inherited thrombophilia and fetal loss: Curr Opin. Hematol. 2000, 7: 290-295. 10.1097/00062752-200009000-00006. Review
129.
Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W: Increased fetal loss in women with heritable thrombophilia. Lancet. 1996, 348: 913-916. 10.1016/S0140-6736(96)04125-6.PubMedCrossRef
130.
Gris JC, Quere I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland ML, Hoffet M, Berlan J, Daures JP, Mares P: Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent – the Nimes Obstetricians and Haematologists Study5 (NOHA5). Thromb Haemost. 1999, 81: 891-899.PubMed
131.
Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM: Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2000, 343: 1015-1018. 10.1056/NEJM200010053431405.PubMedCrossRef
132.
Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ: Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol. 2002, 99: 684-687. 10.1016/S0029-7844(02)01938-5.PubMedCrossRef
133.
Rey E, Kahn SR, David M, Shrier I: Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003, 361: 901-9088. 10.1016/S0140-6736(03)12771-7.PubMedCrossRef
134.
Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS: Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000, 83: 693-697.PubMed
135.
Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M: The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG. 2000, 107: 415-419.PubMedCrossRef
136.
Duley L, Henderson-Smart D, Knight M, King J: Antiplatelet drugs for prevention of pre-eclampsia and its consequences: Systematic review. BMJ. 2001, 322: 329-333. 10.1136/bmj.322.7282.329.PubMedCentralPubMedCrossRef
137.
North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P: Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol. 1995, 35: 357-362.PubMedCrossRef
138.
Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, Eldor A: A Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy. 2001, 20: 35-44. 10.1081/PRG-100104170.PubMedCrossRef
139.
Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA: Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol. 1998, 80: 49-54. 10.1016/S0301-2115(98)00083-9.PubMedCrossRef
140.
Greer IA: Thrombosis in Pregnancy: Maternal and Fetal Issues. Lancet. 1999, 353: 4-10. 10.1016/S0140-6736(98)10265-9.CrossRef
141.
Seligsohn U, Zivelin A: Thrombophilia As a Multigenic Disorder. Thromb Haemost. 1997, 78: 297-301.PubMed
142.
Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB: Prothrombin and Factor V Mutations in Women With a History of Thrombosis During Pregnancy and the Puerperium. N Engl Med. 2000, 342: 374-380. 10.1056/NEJM200002103420602.CrossRef
143.
Greer IA: The Challenge of Thrombophilia in Maternal-Fetal Medicine. N Engl Med. 2000, 342: 424-425. 10.1056/NEJM200002103420610.CrossRef
144.
Turnball A, Tindall VR, Beard RW: Report on confidential enquiries into maternal death in England and Wales 1982–1984. London: HMSO. 1989, Report No:28
145.
Greer IA: Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology. Baillieres Clin. Obstet Gynaecol. 1997, 11: 403-430.PubMedCrossRef
146.
Ferrari E, Jambou D, Fischer F, Appert-Flory A: Maladie Thromboembolique Veineuse Chez La Femme Enceinte: Sang Thrombose Vaisseaux. 1999, 11: 16-19.
147.
Badracco MA, Vessey M: Recurrence of Venous Thromboembolism and the Use of Oral Contraceptives. BMJ. 1974, 2: 215-217.CrossRef
148.
Ginsberg JS, Brill-Edwards P, Burrows RF, Bona R, Prandoni P, Buller HR, Lensing A: Venous Thrombosis During Pregnancy: Leg and Trimester of Presentation. Thromb Haemost. 1992, 67: 519-520.PubMed
149.
Macklon NS, Greer IA, Bowman AW: An Ultrasound Study of Gestational and Postural Changes in the Deep Venous System of the Leg in Pregnancy. Br J Obstet Gynaecol. 1997, 104: 191-197.PubMedCrossRef
150.
Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID: Activated Protein C Sensitivity, Protein C, Protein S and Coagulation in Normal Pregnancy. Thromb Haemost. 1998, 79: 1166-1170.PubMed
151.
Greer IA: Haemostasis and thrombosis in pregnancy. Edited by: Bloom AL, Forbes CD, Thomas DP, and Tuddenham EGD. 1994, Edinburgh: Churchill Livingston, 987-999.
152.
Friend JR, Kakkar VV: The diagnosis of deep venous thrombosis in the puerperium. J Obstet Gynaecol Br Commonw. 1970, 77: 820-823.PubMedCrossRef
153.
Macklon NS, Greer IA: Venous thromboembolic disease in obstetrics and gynaecology: the Scottish Experience. Scott Med. 1996, 41: 83-86.
154.
Ginsberg JS, Hirsh J, Rainbow AJ, Coates G: Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost. 1989, 61: 189-196.PubMed
155.
Finazzi G, Barbui T: Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost. 1994, 71: 15-18.PubMed
156.
Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M: Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990, 63: 319-320.PubMed
157.
Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M: Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost. 1997, 77: 39-43.PubMed
158.
Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Buller HR, Girolami A, Prins MH: Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996, 125: 955-960.PubMedCrossRef
159.
Hallak M, Senderowicz J, Cassel A, Shapira C, Aghai E, Auslender R, Abramovici H: Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol. 1997, 176: 889-893.PubMedCrossRef
160.
McColl MD, Walker ID, Greer IA: A Mutation in the prothrombin gene contributing to venous thrombosis during pregnancy. Br J Obstet Gynaecol. 1998, 105: 923-925.PubMedCrossRef
161.
Lindqvist PG, Svensson PJ, Dahlback B, Marsal K: Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss-a possible evolutionary selection mechanism. Thromb Haemost. 1998, 79: 69-73.PubMed
162.
Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL: A Common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997, 90: 1747-1750.PubMed
163.
164.
Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z: Low molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999, 81: 668-672.PubMed
165.
Nelson-Piercy C, Letsky EA, De Swiet M: Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997, 176: 1062-1068.PubMedCrossRef
166.
Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett JJ, Kakkar VV: Use of low molecular weight heparin in pregnancy. Thromb Haemost. 1992, 68: 652-656.PubMed
167.
Gillis S, Shushan A, Eldor A: Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int Gynaecol Obstet. 1992, 39: 297-301.CrossRef
168.
Fejgin MD, Lourwood DL: Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv. 1994, 49: 424-431.PubMedCrossRef
169.
Harenberg J, Schneider D, Heilmann L, Wolf H: Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis. 1993, 23: 314-320.PubMed
170.
Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM: Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost. 2001, 86: 800-803.PubMed
171.
Macklon NS, Greer IA: Technical note: Compression stockings and posture: a comparative study of their effects on the proximal deep veins of the leg at rest. Br J Radiol. 1995, 68: 515-518.PubMedCrossRef
172.
Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G: Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med. 2000, 343: 1439-1444. 10.1056/NEJM200011163432002.PubMedCrossRef
173.
Brancazio LR, Roperti KA, Stierer R, Laifer SA: Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol. 1995, 173: 1240-1245.PubMedCrossRef
174.
Barbour LA, Smith JM, Marlar RA: Heparin levels to guide thromboembolism prophylaxis during pregnancy. Am J Obstet Gynecol. 1995, 173: 1869-1873.PubMedCrossRef
175.
Hirsh J: Low-molecular-weight heparin for the treatment of venous thromboembolism. Am Heart J. 1998, 135: S336-S342.PubMedCrossRef
176.
Rasmussen C, Wadt J, Jacobsen B: Thromboembolic prophylaxis with low molecular weight heparin during pregnancy. Int Gynaecol Obstet. 1994, 47: 121-125.CrossRef
177.
Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E: Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol. 1996, 87: 380-383. 10.1016/0029-7844(95)00452-1.PubMedCrossRef
178.
Casele HL, Laifer SA, Woelkers DA, Venkataramanan R: Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999, 181: 1113-1117.PubMedCrossRef
179.
Thomson AJ, Walker ID, Greer IA: Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy. Lancet. 1998, 352: 1904-PubMedCrossRef
180.
Aburahma AF, Boland JP: Management of Deep Vein Thrombosis of the lower extremity in pregnancy: a challenging dilemma. Am Surg. 1999, 65: 164-167.PubMed
181.
182.
Lockshin MD: Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost. 1999, 82: 641-648.PubMed
183.
Kutteh WH, Ermel LD: A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996, 35: 402-407.PubMedCrossRef
184.
Lanska DJ, Kryscio RJ: Stroke and Intracranial Venous Thrombosis During Pregnancy and Puerperium. Neurology. 1998, 51: 1622-1628.PubMedCrossRef
185.
Mas JL, Lamy C: Stroke in pregnancy and the puerperium. J Neurol. 1998, 245: 305-313. 10.1007/s004150050224.PubMedCrossRef
186.
Kittner SJ, Stern BJ, Feeser BR, Hebel R, Nagey DA, Buchholz DW, Earley CJ, Johnson CJ, Macko RF, Sloan MA, Wityk RJ, Wozniak MA: Pregnancy and the risk of stroke. N Engl Med. 1996, 335: 768-774. 10.1056/NEJM199609123351102.CrossRef
187.
Rizk B, Meagher S, Fisher AM: Severe ovarian hyperstimulation syndrome and cerebrovascular accidents. Hum Reprod. 1990, 5: 697-698.PubMed
188.
Kaaja R, Siegberg R, Tiitinen A, Koskimies A: Severe ovarian hyperstimulation syndrome and deep venous thrombosis [Letter]. Lancet. 1989, 2: 1043-10.1016/S0140-6736(89)91057-X.PubMedCrossRef
189.
Kupferminc MJ, Yair D, Bornstein NM, Lessing JB: Transient focal neurological deficits during pregnancy in carriers of inherited thrombophilia. Stroke. 2000, 31: 892-895.PubMedCrossRef
190.
Bertina RM, Rosendaal FR: Venous thrombosis-the Interaction of genes and environment. N Engl J Med. 1998, 338: 1840-1841. 10.1056/NEJM199806183382510.PubMedCrossRef
Metadata
Title
Thrombophilia and pregnancy
Author
Michael J Kupferminc
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2003
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/1477-7827-1-111

Other articles of this Issue 1/2003

Reproductive Biology and Endocrinology 1/2003 Go to the issue

Research

Late gestation modulation of fetal glucocorticoid effects requires the receptor for leukemia inhibitory factor: an observational study

Research

SPAM1 (PH-20) protein and mRNA expression in the epididymides of humans and macaques: utilizing laser microdissection/RT-PCR

Review

Regulation of intraluteal production of prostaglandins

Review

Sperm preparation for ART

Research

Nitric oxide synthase activity in human trophoblast, term placenta and pregnant myometrium

Review

Will cloned animals suffer premature aging – The story at the end of clones' chromosomes